The US Food and Drug Administration has started conducting collaborative reviews with foreign regulators under a new initiative that could help streamline global clinical trials while also speeding the approval of supplemental indications for cancer drugs in smaller countries.
On 17 September, the FDA’s Oncology Center of Excellence (OCE) announced the launch of Project Orbis, a collaboration that provides...








